Multiple myeloma trials in Netherlands

In Netherlands 33 Also abroad 704

33 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Where
Dordrecht, Nijmegen
Age
18 years and over
People
410 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT05730036 · EU 2022-501396-62-00
Phase 1Taking people
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Where
Amsterdam, Groningen
Age
18 years and over
People
317 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT05137054 · EU 2023-506247-42-00
Phase 2Taking people
A study with new methods to monitor newly diagnosed multiple myeloma in participants being treated with a new treatment combination - TAURUS
Where
Amsterdam, Arnhem, Breda, Groningen, Hoorn Nh, Rotterdam
Age
18 years and over
People
240 worldwide
Run by
European Myeloma Network B.V.
See details and how to joinNCT06189833 · EU 2023-505221-14-00
Phase 3Taking people
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Where
Breda, Hoofddorp, Nijmegen, Rotterdam
Age
18 years and over
People
915 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT07222761 · EU 2024-519504-27-00
Phase 2Taking people
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Where
Amsterdam, Utrecht
Age
18 years and over
People
510 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT04634552 · EU 2023-504581-29-00
Phase 4Taking people
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Where
Amsterdam, Groningen, Rotterdam, Utrecht
Age
18 years and over
People
295 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05201781 · EU 2023-505530-10-00
Phase 3Taking people
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Where
Amsterdam, Apeldoorn, Delft, Geleen, Nieuwegein
Age
18 years and over
People
1,590 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05552222 · EU 2023-503442-30-00
Phase 1Taking people
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Where
Amsterdam, Groningen, Utrecht
Age
18 years and over
People
180 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05652335 · EU 2023-503679-12-00
Phase 3Taking people
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Where
Amsterdam, Groningen, Nieuwegein, Nijmegen, Rotterdam, 's-Gravenhage
Age
18 years and over
People
400 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07258511 · EU 2025-522007-18-00
Phase 3Taking people
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
Where
Eindhoven, Groningen, Nieuwegein, Sittard-Geleen, Utrecht
Age
18 years and over
People
1,000 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07665450
Phase 3Taking people
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Where
Amsterdam, Maastricht, Nijmegen, Utrecht
Age
18 years and over
People
440 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06615479 · EU 2024-515279-37-00
Phase 3Taking people
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Where
Dordrecht, Groningen
Age
18 years and over
People
1,060 worldwide
Run by
Pfizer
See details and how to joinNCT05623020 · EU 2024-514139-50-00
Phase 3Taking people
A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Where
Eindhoven, Geleen, Groningen, Nieuwegein, Nijmegen, Utrecht
Age
18 years and over
People
423 worldwide
Run by
Janssen Cilag International
See details and how to join2026-526654-14-01 · EU 2026-526654-14-01
Phase 3Taking people
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Where
Amsterdam, Nieuwegein
Age
18 years and over
People
183 worldwide
Run by
Takeda
See details and how to joinNCT06980480 · EU 2024-518420-80-00
Phase 3Taking people
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Where
Alkmaar, Amsterdam, Dordrecht, Eindhoven, Groningen, Hoorn Nh, Nieuwegein, Rotterdam
Age
18 years and over
People
1,594 worldwide
Run by
European Myeloma Network B.V.
See details and how to joinNCT05243797 · EU 2023-510384-36-00
Phase 2Taking people
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Where
Amsterdam, Dordrecht, Rotterdam
Age
18 years and over
People
210 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06500884 · EU 2023-506260-14-00
Phase 1Taking people
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
Where
Amsterdam, Groningen, Utrecht
Age
18 years and over
People
276 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06768489 · EU 2024-515316-44-00
Phase 3Taking people
A long-term follow-up study for patients treated with Galapagos CAR T cell therapies
Where
Amsterdam, Leiden, Maastricht, Rotterdam
Age
18 years and over
People
309 worldwide
Run by
Lakefront Biotherapeutics
See details and how to join2023-510173-34-00 · EU 2023-510173-34-00
Phase 1/2Taking people
[68Ga]Ga-PentixaFor positron emission tomography for improved risk and disease assessment in myeloma
Where
Amsterdam
Age
18 years and over
People
90 worldwide
Run by
University Of Antwerp
See details and how to join2022-501811-14-00 · EU 2022-501811-14-00
Phase 2Taking people
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
Where
Amersfoort, Hoofddorp, 's-Gravenhage
Age
18 years and over
People
200 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07227311 · EU 2025-523117-28-00
Phase 3Taking people
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Where
Maastricht, Rotterdam
Age
18 years and over
People
893 worldwide
Run by
Pfizer
See details and how to joinNCT05020236 · EU 2023-509208-14-00
Phase 3Taking people
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Where
Dordrecht, Maastricht, Rotterdam
Age
18 years and over
People
492 worldwide
Run by
Pfizer
See details and how to joinNCT06152575 · EU 2023-507871-23-00
Phase 2Taking people
DRUP trial
Where
Alkmaar, Almelo, Amersfoort, Amsterdam, Apeldoorn, Arnhem, Breda, Delft, Deventer, Drachten, Ede Gld, Eindhoven, Gorinchem, Groningen, Heerlen, Hilversum, Hoofddorp, Hoogeveen, Leeuwarden, Leiden, Leidschendam, Maastricht, Nijmegen, Roosendaal, Rotterdam, Schiedam, 's-Gravenhage, Tilburg, Utrecht, Venlo, Zwolle
Age
18 years and over
People
3,000
Run by
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
See details and how to joinNCT02925234 · EU 2023-509152-33-00
Phase 1/2Taking people
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Where
Amsterdam, Groningen, Nijmegen, Rotterdam, Utrecht
Age
18 years and over
People
220 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06292780 · EU 2023-507809-34-00
Phase 1Taking people
Long-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapies
Where
Amsterdam
People
7 worldwide
Run by
USWM Ct LLC
See details and how to join2024-513033-21-00 · EU 2024-513033-21-00